1. Introduction

Cross-border recognition of Good Manufacturing Practice (GMP) inspections is an important aspect of international pharmaceutical regulation. It refers to the legal and administrative arrangements through which one country's pharmaceutical regulatory authority accepts, relies upon, or recognises GMP inspection findings made by another country's regulatory authority.

Good Manufacturing Practice (GMP) establishes minimum standards for the manufacture, testing, packaging, storage and distribution of pharmaceutical products to ensure that medicines are consistently safe, effective and of appropriate quality.

For example, suppose a pharmaceutical manufacturing company operates in India and exports medicines to the European Union, United States, Japan or Australia. The manufacturing facility may be inspected by India's Central Drugs Standard Control Organisation (CDSCO). The importing country's regulator may decide to rely on the Indian inspection report rather than conduct an entirely new inspection.

However, recognition does not necessarily mean automatic acceptance. The importing country may still require:

Verification of the foreign regulatory authority's competence.

Compliance with its own GMP standards.

Access to inspection reports and supporting evidence.

Assessment of critical deficiencies.

Follow-up inspections where necessary.

Enforcement action where serious manufacturing violations exist.

The central legal question is whether a regulatory authority can lawfully rely on another country's inspection without compromising public health, pharmaceutical quality and regulatory accountability.

2. Meaning and Legal Nature of Cross-Border GMP Recognition

Cross-border GMP recognition is a regulatory cooperation mechanism involving the acceptance or reliance upon foreign inspection outcomes.

It generally operates through three mechanisms:

A. Mutual Recognition Agreements (MRAs)

Two or more countries formally agree to recognise specified GMP inspection systems and regulatory decisions, subject to agreed conditions.

B. Inspection reliance arrangements

A regulator uses another competent authority's inspection reports, findings or compliance certificates to inform its own regulatory decisions without necessarily granting complete mutual recognition.

C. International harmonisation and cooperation

Regulatory authorities follow common GMP standards and cooperate through international organisations and inspection networks.

An important distinction exists between recognition of an inspection and recognition of a pharmaceutical product's marketing authorisation. Recognition of a GMP inspection does not automatically authorise the medicine to be sold in the importing country.

3. International Legal Framework

A. World Health Organization (WHO) GMP standards

The WHO has developed internationally recognised GMP guidelines to promote consistent pharmaceutical manufacturing standards.

The WHO GMP framework addresses:

Quality management systems.

Personnel qualifications and training.

Premises and equipment.

Sanitation and hygiene.

Documentation and record keeping.

Production controls.

Quality control laboratories.

Complaints and product recalls.

Contract manufacturing.

Self-inspection and quality audits.

WHO standards provide a common technical foundation, but they do not independently create a universal legal obligation requiring every country to recognise another country's inspection certificate.

The WHO Global Benchmarking Tool and WHO Listed Authorities framework also help assess regulatory-system maturity and regulatory capability.

B. Pharmaceutical Inspection Co-operation Scheme (PIC/S)

The Pharmaceutical Inspection Co-operation Scheme (PIC/S) is a major international cooperation arrangement for pharmaceutical inspection authorities.

Its principal objectives include:

Harmonisation of GMP inspection procedures.

Development of common inspection standards.

Training and qualification of inspectors.

Exchange of regulatory information.

Improvement of confidence between inspection authorities.

Promotion of consistent pharmaceutical quality systems.

An important legal distinction is that PIC/S membership does not automatically establish a binding mutual-recognition obligation.

PIC/S is a non-binding cooperative arrangement. Its participating authorities are not generally required to accept every inspection conclusion made by another participant.

Public Health+2

C. European Union–United States Mutual Recognition Agreement

The EU–US pharmaceutical GMP Mutual Recognition Agreement is a significant example of formal cross-border recognition.

Its pharmaceutical sectoral annex became operational on 1 November 2017 for human medicines. It was subsequently extended to veterinary medicines from 30 May 2023.

Under the arrangement:

FDA inspections can be recognised by participating EU authorities.

EU inspections can be recognised by the FDA.

Inspection reports can be exchanged.

Duplicate inspections can be reduced.

Regulatory authorities can concentrate resources on higher-risk manufacturing facilities.

However, regulators retain the power to inspect foreign facilities where necessary.

The EU and US have also developed arrangements for reliance on certain FDA inspections conducted outside US territory, with the EU provision applying from 1 October 2025 on a voluntary, case-by-case and risk-based basis.

European Medicines Agency (EMA)+2

D. European Union–Canada and European Union–Japan arrangements

The EU has established GMP mutual-recognition arrangements with several international partners, including Canada and Japan.

These arrangements facilitate:

Recognition of inspection outcomes.

Exchange of inspection information.

Cooperation concerning pharmaceutical quality defects.

Reduction or waiver of certain import-related batch-testing requirements.

The exact scope varies according to the agreement and product category. Certain biological products, blood-derived products, advanced therapies and other specialised products may be excluded or subject to separate arrangements.

European Medicines Agency (EMA)+1

4. Legal Framework in India

India is an important pharmaceutical manufacturing and export jurisdiction. Cross-border recognition of Indian GMP inspections therefore has considerable implications for manufacturers, regulators and importing countries.

The principal legal framework includes the following.

A. Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act, 1940 establishes the principal statutory framework for regulating the manufacture, import, distribution and sale of drugs in India.

Important provisions include:

These provisions provide the statutory foundation for domestic regulatory inspection and enforcement.

An Indian GMP certificate may be relevant evidence for an overseas regulator, but the foreign authority must determine whether it is legally acceptable under its own regulatory framework.

B. Drugs Rules, 1945

The Drugs Rules, 1945 provide detailed regulatory requirements for pharmaceutical manufacturing.

Schedule M is particularly important because it prescribes GMP requirements and requirements of premises, plant and equipment for pharmaceutical products.

The revised Schedule M requirements strengthen:

Pharmaceutical quality management systems.

Risk management.

Validation and qualification.

Documentation controls.

Personnel training.

Product quality review.

Computerised systems.

Quality assurance and quality control.

The revised requirements were introduced through the Drugs Rules amendment in December 2023, with implementation arrangements and extensions for eligible manufacturers.

C. Central Drugs Standard Control Organisation (CDSCO)

The Central Drugs Standard Control Organisation (CDSCO) is India's central drug regulatory authority.

Its responsibilities include:

Regulatory oversight of drugs and specified medical products.

Coordination with State Drug Control Authorities.

Inspection and enforcement activities within its statutory jurisdiction.

Import-related regulatory functions.

Evaluation of regulatory compliance.

International regulatory cooperation.

D. Legal position concerning foreign recognition

India's participation in international regulatory cooperation does not mean that every foreign GMP certificate automatically becomes binding in India.

Similarly, an Indian GMP inspection certificate does not automatically compel the EU, US, Japan or Australia to accept it.

The importing authority must examine the applicable legislation, recognition arrangements, inspection authority's competence, product category and relevant compliance evidence.

5. Procedure for Cross-Border Recognition of GMP Inspections

Cross-border recognition generally involves the following stages.

Recognition procedure

Assessment of the foreign regulator

The importing country evaluates the inspection authority's legal powers, technical competence, staffing and inspection procedures.

Verification of GMP standards

The authority examines whether the exporting country's standards are sufficiently equivalent to the applicable domestic standards.

Inspection report exchange

Inspection reports, compliance certificates and relevant corrective-action information are exchanged through authorised channels.

Assessment of inspection findings

Critical, major and minor deficiencies are examined, including their effect on product quality and patient safety.

Recognition decision

The importing regulator decides whether to accept or rely upon the foreign inspection outcome.

Post-recognition monitoring

Regulators monitor complaints, adverse events, recalls, quality defects and subsequent inspection results.

Recognition may be refused or suspended where serious regulatory concerns arise.

6. Important Case Laws and Judicial Decisions

An important point for legal research is that there is relatively little reported judicial litigation directly interpreting pharmaceutical GMP mutual-recognition agreements. The following decisions are relevant to cross-border inspection reliance, regulatory compliance, pharmaceutical manufacturing responsibility and enforcement.

Case 1. Noramco LLC v. Dishman USA Inc. (2024)

Directly relevant to cross-border GMP inspection

Citation: Noramco LLC v. Dishman USA Inc., No. 23-1396 (3d Cir. July 16, 2024).

Facts:

The dispute concerned a pharmaceutical manufacturing facility located in India. The facility was inspected by representatives of the European Directorate for the Quality of Medicines and HealthCare (EDQM) and Swissmedic.

The inspection identified critical and major GMP deficiencies. The European regulatory body subsequently determined that the facility was not compliant with GMP requirements and suspended relevant Certificates of Suitability.

The parties then disputed the contractual consequences of the inspection findings and the rejection of pharmaceutical material manufactured at the Indian facility.

Legal issues:

Whether foreign regulatory inspection findings could affect commercial contractual obligations.

Whether a manufacturing facility's GMP non-compliance could justify rejection of pharmaceutical materials.

Whether a manufacturer was required to disclose regulatory non-compliance to its customer.

Whether inspection findings concerning other substances manufactured at the same facility were relevant to the contractual dispute.

Legal significance:

The case demonstrates that foreign regulatory inspections can have substantial consequences for pharmaceutical supply contracts, even where the inspection concerns manufacturing operations beyond the particular product involved in a commercial transaction.

It also illustrates the importance of contractual provisions governing regulatory disclosures, inspection findings, product quality and rejection rights.

Relevance to cross-border recognition: Foreign inspection findings may become important evidence in domestic commercial litigation. However, this case should not be interpreted as establishing a general international obligation to recognise every foreign GMP inspection.

Justia Law

Case 2. United States v. Park (1975)

Citation: 421 U.S. 658 (1975).

Court: Supreme Court of the United States.

Facts:

The case concerned violations of the Federal Food, Drug, and Cosmetic Act involving insanitary conditions in food warehouses.

The Supreme Court considered the responsibility of a corporate officer who had authority and responsibility to prevent or correct violations.

Legal principle:

The Court recognised the possibility of imposing criminal liability upon a responsible corporate officer under the FDCA without requiring proof that the officer personally participated in each individual violation.

Relevance to GMP recognition:

Although the case concerned food sanitation rather than pharmaceutical GMP inspections, its reasoning is relevant to regulatory accountability.

A foreign inspection finding identifying serious manufacturing deficiencies may raise questions about the responsibility of corporate officers, quality assurance personnel and manufacturing management.

It demonstrates that international recognition of inspection outcomes must be accompanied by effective domestic enforcement mechanisms.

Case 3. State of Haryana v. Brij Lal Mittal (1998)

Citation: (1998) 5 SCC 343.

Court: Supreme Court of India.

Facts:

The case concerned criminal liability arising from alleged violations of the Drugs and Cosmetics Act, 1940.

The Supreme Court examined the statutory basis for prosecuting persons associated with a pharmaceutical company.

Legal principle:

The Court explained that directors cannot automatically be prosecuted merely because they hold that designation. The statutory requirements concerning responsibility for the company's business must be satisfied.

Relevance to GMP recognition:

When a foreign regulator identifies GMP violations at an Indian pharmaceutical manufacturing facility, Indian enforcement authorities must determine the liability of the appropriate persons under Indian law.

A foreign inspection report may provide relevant evidence, but criminal liability must be established according to Indian statutory requirements and applicable evidentiary rules.

Case 4. Municipal Corporation of Delhi v. Ghisa Ram (1967)

Citation: AIR 1967 SC 970.

Court: Supreme Court of India.

Facts:

The case involved prosecution concerning an allegedly adulterated food sample. The sample deteriorated because of delay, affecting the accused's opportunity to obtain reliable analysis.

Legal principle:

The Supreme Court emphasised the importance of procedural safeguards and the ability of an accused person to exercise statutory rights concerning the analysis of samples.

Relevance to GMP recognition:

The case is relevant by analogy to the evidentiary treatment of pharmaceutical inspection samples.

Cross-border inspection systems should ensure:

Proper sample collection.

Documented chain of custody.

Preservation of samples.

Valid laboratory procedures.

Access to relevant analytical records.

Fair opportunity to challenge adverse findings.

It is not a direct GMP mutual-recognition judgment, but its procedural reasoning is relevant to regulatory evidence.

Case 5. EU–US Pharmaceutical GMP Mutual Recognition Framework (2017)

Legal instrument: Pharmaceutical Good Manufacturing Practices Sectoral Annex to the 1998 EU–US Mutual Recognition Agreement, as amended in 2017.

Relevant provision: Article 8 – Recognition of Inspections.

This is a treaty-based regulatory framework rather than a judicial judgment.

Article 8 establishes that the parties should recognise pharmaceutical inspections and accept official GMP documents issued by recognised authorities.

However, recognition may be withheld in specified circumstances, including:

Material inconsistencies in inspection reports.

Inadequacies in the inspection findings.

Quality defects discovered through post-market surveillance.

Other serious concerns about product quality or consumer safety.

The authority declining recognition must notify the other party of its reasons and may request clarification.

Legal significance: This framework establishes that mutual recognition is conditional and that public-health protection takes priority over automatic acceptance of foreign regulatory documents.

EUR-Lex+1

7. Grounds for Refusal of Foreign GMP Inspection Recognition

A regulatory authority may refuse to recognise an overseas inspection where sufficient legal or technical grounds exist.

Important legal principle: A regulator should distinguish between a genuine disagreement about technical standards and evidence of a serious public-health risk. Refusal of recognition should be supported by reasons and the applicable legal framework.

8. Confidentiality and Exchange of Inspection Reports

Cross-border GMP recognition requires the exchange of sensitive regulatory information.

Inspection reports may contain:

Manufacturing processes.

Proprietary formulations.

Quality-control procedures.

Technical specifications.

Validation reports.

Production records.

Corrective and preventive action plans (CAPA).

Information concerning commercial operations.

Consequently, information-sharing arrangements must protect trade secrets and confidential business information.

For example, the FDA and European authorities have developed confidentiality arrangements permitting the exchange of full pharmaceutical inspection reports, including certain trade-secret information, subject to legal safeguards.

In the United States, the Food and Drug Administration Safety and Innovation Act 2012 strengthened the FDA's ability to exchange certain confidential information with qualifying foreign regulatory authorities.

U.S. Food and Drug Administration+2

9. Recognition of Foreign Inspections and Pharmaceutical Importation

Recognition of GMP inspections is closely connected with pharmaceutical import controls.

Under the EU pharmaceutical regulatory framework, foreign manufacturing facilities must satisfy applicable GMP requirements. Where an applicable MRA exists, the importing authority may rely upon the recognised foreign inspection system.

Three separate legal concepts must be distinguished:

These are related but not identical.

For example, under the EU–US arrangement, recognition can reduce duplicated inspections and facilitate the exchange of regulatory information. Certain agreements also permit the waiver of import batch testing.

However, recognition of a foreign inspection does not eliminate all responsibilities of the importing manufacturer, importer or marketing authorisation holder.

European Medicines Agency (EMA)+2

10. Cross-Border GMP Recognition and Australia

Australia provides an important example of a regulatory system that uses international inspection cooperation while retaining domestic regulatory control.

The Therapeutic Goods Administration (TGA) uses international GMP agreements and arrangements to assess evidence of manufacturing compliance.

Its framework includes:

Mutual Recognition Agreements.

Pharmaceutical Inspection Co-operation Scheme cooperation.

GMP clearance procedures.

Assessment of foreign GMP certificates.

Risk-based evaluation of overseas manufacturing facilities.

Importantly, PIC/S membership alone does not guarantee acceptance of every inspection. The TGA imposes conditions on the origin and territorial circumstances of the inspection evidence.

For example, it states that evidence from a PIC/S participating authority will not be accepted through its relevant pathway where the inspection was performed outside that authority's territory or before its accession to PIC/S.

Therapeutic Goods Administration (TGA)

This illustrates how national regulators can recognise international inspection expertise while maintaining independent control over imported medicines.

11. Legal Challenges in Cross-Border GMP Recognition

A. Regulatory sovereignty

Each country has sovereign authority to regulate medicines entering its domestic market.

A foreign regulator cannot automatically exercise enforcement powers within another country's territory.

Consequently, recognition agreements must respect the legal powers of both authorities.

B. Differences in GMP standards

Although international GMP standards are increasingly harmonised, differences may remain in:

Sterile manufacturing requirements.

Biological product manufacturing.

Active pharmaceutical ingredient production.

Data integrity.

Computerised systems.

Contamination control.

Validation and qualification.

A foreign inspection may therefore be insufficient for assessing a particular domestic regulatory requirement.

C. Regulatory accountability

When a recognised inspection fails to identify serious manufacturing violations, difficult questions arise.

For example:

Was the inspection conducted competently?

Were important manufacturing deficiencies overlooked?

Did the exporting regulator possess sufficient information?

Did the importing regulator reasonably rely upon the foreign report?

Which authority is responsible for corrective enforcement?

The existence of an MRA does not automatically transfer legal responsibility from one regulator to another.

D. Pharmaceutical supply-chain complexity

Modern pharmaceutical products may involve multiple countries.

A single medicine may involve:

API manufacturing in India.

Formulation in another country.

Packaging in Europe.

Quality testing in a third jurisdiction.

Distribution through an international pharmaceutical wholesaler.

Recognition of one manufacturing site's inspection does not establish compliance at every other site in the supply chain.

E. Inspection fraud and falsification

Foreign GMP certificates may be falsified or improperly obtained.

Regulators therefore require verification mechanisms, including:

Official regulatory databases.

Certificate authentication.

Inspection-report verification.

Regulatory communications.

Follow-up inspections.

F. Emergency regulatory action

A previously recognised facility may subsequently experience serious contamination, data-integrity failures or manufacturing defects.

The importing regulator must retain the ability to suspend recognition, restrict imports, initiate recalls or require additional inspections where legally justified.

12. Liability Arising from Incorrect Recognition

Cross-border GMP recognition may generate several forms of legal liability.

A particularly important issue is the distinction between regulatory reliance and legal responsibility.

Even if an importing regulator accepts a foreign inspection report, the importer and marketing authorisation holder cannot necessarily escape their independent statutory responsibilities.

13. Relationship with Other International Legal Instruments

Cross-border GMP recognition also interacts with several international legal frameworks.

1. WTO Agreement on Technical Barriers to Trade (TBT)

The TBT Agreement encourages the use of international standards and conformity-assessment cooperation. However, it does not create a general obligation to recognise every foreign pharmaceutical GMP inspection.

2. WTO Agreement on the Application of Sanitary and Phytosanitary Measures (SPS)

The SPS Agreement may become relevant where pharmaceutical-related measures also fall within its sanitary and phytosanitary scope. Ordinary pharmaceutical GMP regulation is generally analysed under the applicable pharmaceutical regulatory framework and potentially the TBT Agreement, rather than automatically under SPS.

3. International Council for Harmonisation (ICH)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) promotes harmonisation of pharmaceutical technical requirements.

Its Q7, Q9 and Q10 guidelines are particularly relevant to GMP, quality-risk management and pharmaceutical quality systems.

4. WHO regulatory framework

WHO GMP standards and regulatory benchmarking contribute to international confidence in national inspection systems.

5. PIC/S framework

PIC/S promotes common inspection standards and regulatory cooperation without itself establishing universal mandatory mutual recognition.

14. Important Legal Principles Emerging from the Case Laws

The cases and regulatory instruments discussed above support several important principles.

1. Regulatory competence: A foreign inspection should be recognised only where the inspection authority satisfies the applicable competence requirements.

2. Public-health protection: Recognition cannot prevent an importing regulator from acting against serious risks to patients.

3. Reasoned decisions: Refusal to recognise an inspection should be supported by appropriate reasons under the relevant legal framework.

4. Evidence integrity: Inspection findings must be supported by reliable documentation, laboratory evidence and appropriate procedures.

5. Corporate accountability: Manufacturers and responsible officers remain subject to applicable domestic statutory obligations.

6. Contractual accountability: Regulatory inspection failures may create commercial consequences independently of regulatory penalties.

7. Regulatory independence: Mutual recognition does not eliminate the importing authority's legal powers.

8. Proportionality: Regulatory restrictions should be proportionate to the seriousness of the identified risk, subject to the governing legislation.

15. Suggestions for Legal and Regulatory Reform

The following reforms could improve international GMP recognition:

Establish transparent bilateral and multilateral GMP recognition agreements.

Develop common standards for evaluating foreign inspectorates.

Improve electronic verification of GMP certificates.

Establish secure international inspection-report databases.

Develop common definitions of critical, major and minor deficiencies.

Introduce mandatory notification of serious GMP violations.

Establish procedures for challenging inaccurate inspection findings.

Improve cooperation between CDSCO, FDA, EMA, TGA and other regulatory authorities.

Develop clear rules for recognition of inspections conducted in third countries.

Establish independent mechanisms for reviewing recognition refusals.

Improve regulatory accountability for negligent reliance on foreign inspection findings.

India could also strengthen its international inspection cooperation by improving regulatory transparency, inspection-report exchange and alignment with internationally accepted GMP standards.

16. Conclusion

Cross-border recognition of GMP inspections is an essential component of modern international pharmaceutical regulation. It facilitates pharmaceutical trade, reduces duplication of regulatory inspections, improves international cooperation and makes better use of regulatory resources.

However, recognition is not equivalent to unrestricted acceptance of foreign regulatory decisions. It depends upon the competence of the foreign inspection authority, equivalence of applicable standards, reliability of inspection reports, confidentiality safeguards and continuing protection of public health.

The EU–US Pharmaceutical GMP Mutual Recognition Agreement demonstrates how formal international arrangements can establish a structured system of regulatory reliance. PIC/S and WHO frameworks provide additional mechanisms for harmonisation and regulatory confidence.

For India, the Drugs and Cosmetics Act, 1940, the Drugs Rules, 1945, revised Schedule M and CDSCO's regulatory functions provide the domestic foundation for GMP compliance. Greater international recognition of Indian inspection outcomes requires sustained regulatory cooperation, technical competence and transparent enforcement.

Ultimately, the governing legal principle is that international regulatory cooperation should facilitate recognition of reliable foreign inspections without compromising national regulatory sovereignty, pharmaceutical quality or patient safety.

17. Important Authorities and References for Further Research

Particularly useful case-law references:

Noramco LLC v. Dishman USA Inc., No. 23-1396 (3d Cir. 2024).

United States v. Park, 421 U.S. 658 (1975).

State of Haryana v. Brij Lal Mittal, (1998) 5 SCC 343.

Municipal Corporation of Delhi v. Ghisa Ram, AIR 1967 SC 970.

Research qualification: The first case directly concerns foreign GMP inspection findings and their commercial consequences. The remaining judgments concern related regulatory accountability, pharmaceutical enforcement or evidentiary principles; they should not be cited as decisions directly establishing cross-border GMP mutual recognition.

Official research sources

European Medicines Agency – Mutual Recognition Agreements

EU–US Pharmaceutical GMP Sectoral Annex

US FDA – EU Mutual Recognition Agreement

European Commission – International Pharmaceutical Cooperation

Australian TGA – International GMP Agreements

Noramco LLC v. Dishman USA Inc. (2024)